| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbb9988975944138378abe4549a8d0f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-536 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate |
2015-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95f547a141de45dfe3715689de488d08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b99bfcc1421f6489f2adf078ff89ae92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0b7043bb8cc75d91467cc6016bac50f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f02826b897279b3645c99babe896f75d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163b600c498d2e99ae527bd73e1d3ab6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8929adc6733a3f1f1cfb0f331f52268
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8190df7ca3874dc45ecb9adf235a446e |
| publicationDate |
2015-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015106311-A1 |
| titleOfInvention |
Cell surface prostate cancer antigen for diagnosis |
| abstract |
The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106053815-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016168885-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10577418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3209686-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11198738-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3617231-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106053815-A |
| priorityDate |
2014-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |